Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX ® -GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout the duration of the Phase 1 clinical study. In this reported study, PENNVAX-GP plasmids were delivered intradermally or intramuscularly with CELLECTRA ® device in healthy volunteers. More specifically, the study results demonstrated that PENNVAX-GP delivered intradermally (ID) with CELLECTRA generated equivalent or superior immune responses compared to the delivery via intramuscular (IM) route using the same delivery device, with ID delivery using only one-fifth of the dose compared to IM delivery. These results are from a study supported by the HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in collaboration with Inovio. The clinical and scientific data were reported at the Research for Prevention (HIVR4P) Conference held in Madrid, Spain by Protocol Chair of the HVTN 098 study, Dr. Srilatha Edupuganti, MD, MPH, Associate Professor of Medicine, Division of Infectious Disease, Department of Medicine at Emory University.